In 2022, not a single new company chose to list on Hong Kong’s Growth Enterprises Market. Not one. For a platform built to launch fast-growing businesses onto public markets, that’s a strange number to sit with.
Yet a few years later, the growth enterprises market is having something of a comeback. Fresh listing rules, a wave of research-heavy startups, and renewed investor curiosity are pulling life back into a corner of finance many had quietly written off.
So what is the growth enterprises market, and why should founders or investors care in 2026? Let’s get into it.
What Is the Growth Enterprises Market, Exactly?
The growth enterprises market, often shortened to GEM, is a stock exchange board built for small and medium-sized companies that are expanding fast but don’t yet have the profit history main boards demand. In Hong Kong, GEM is a board of the Stock Exchange of Hong Kong for growth companies that don’t meet the profitability or track record requirements of the main board, and it opened back in 1999.
China runs a similar concept. Its own version of the growth enterprise market is a secondary market created to support entrepreneurship and innovation, aimed at startups with independent innovation capabilities. Different country, same basic idea: give young, ambitious companies a door into public markets before they’re “ready” by traditional standards.
This isn’t a niche curiosity, either. It’s a deliberate bridge between private funding rounds and a full-blown public listing.
How Does It Actually Work?
Here’s the simple version. A growth enterprises market is a segment of financial markets built for companies growing quickly that don’t meet the strict requirements of main stock exchanges, usually startups or SMEs with strong future potential rather than immediate profits. Instead of grilling a company on five years of earnings, regulators look at trajectory, innovation, and capacity to scale.
That shift matters. Traditional bank loans want collateral. Venture capital wants equity and often a say in decisions. The growth enterprises market offers a third path, letting companies raise public money earlier without giving up quite as much control.
Eligibility, in Plain Numbers
The bar isn’t zero, though. In Hong Kong, a company typically needs at least two financial years of trading record, a market capitalisation of at least HK$250 million at listing, and aggregate revenue of at least HK$100 million across the two most recent audited years, with year-on-year growth.
There’s also a newer route for companies that prioritize research over revenue. An R&D-focused applicant can qualify with at least HK$30 million spent on research over two years, as long as that spending equals at least 15% of total operating expenditure.
In short:
- Two years minimum operating history
- HK$250 million minimum market cap
- HK$100 million minimum aggregate revenue with growth
- Or, an R&D-heavy alternative path for pre-profit innovators
The 2024 Reform That Quietly Changed the Game
Here’s where it gets interesting. GEM listing activity in Hong Kong had been sliding since 2019, and there wasn’t a single new listed issuer in 2022. That’s the stat from the intro, and regulators clearly noticed.
So, on January 1, 2024, new rules kicked in. The reforms introduced a new alternative eligibility test for R&D-intensive companies that lack a track record of positive operating cash flow, and they set up a streamlined mechanism for moving from GEM to the Main Board. Lock-up periods for controlling shareholders got shorter too, and mandatory quarterly reporting was scrapped in favor of best-practice guidance.
It wasn’t the platform’s first stumble, either. The dot-com crash had wiped out a large share of GEM’s earliest listed companies, and a 2018 restructuring removed the smooth transfer path to the Main Board, which arguably broke the original logic of listing there at all.
Honestly, the R&D eligibility test feels like the most meaningful fix of the bunch. It finally lets pre-revenue, science-heavy startups in the front door instead of forcing them to fake profitability metrics they don’t have yet.
Pros and Cons: Who Actually Benefits?
For companies, the upside is straightforward:
- Easier entry than a Main Board listing
- Access to public capital earlier in the company’s life
- A built-in upgrade path once the business matures
- Lower compliance costs than full-blown exchange rules
For investors, though, it’s a mixed bag. GEM runs on a “buyer beware” philosophy backed by heavy disclosure requirements, putting more responsibility on investors to do their own homework rather than leaning on the exchange to vet quality. Volatility tends to run higher, and liquidity can be thin compared to blue-chip stocks.
Growth Enterprises Market vs. the Main Board
Think of it like minor league baseball. The growth enterprises market is where promising players get real playing time, build a track record, and prove they can handle pressure before getting called up to the majors. The Main Board, in this analogy, is the majors: higher stakes, deeper scrutiny, bigger crowds.
Neither version is “better.” They’re built for different stages of the same journey.
What Experts Are Watching in 2026
“It’s no longer a dumping ground for companies that couldn’t make the cut elsewhere,” says one Hong Kong-based capital markets advisor who’s tracked GEM since the 2024 overhaul. “The reforms gave it an actual reason to exist again.”
That sentiment lines up with what’s happening on the ground. As of 2026, more biotech and deep-tech firms are exploring GEM specifically because of the R&D eligibility path, rather than treating it as a last resort.
Why This Market Still Matters
Growth enterprise markets exist because economies need a feeder system for ambitious companies. A small slice of fast-growing firms tends to create an outsized share of new jobs, and locking those companies out of public capital until they’re “safe” enough for a main exchange slows that whole engine down.
Looking ahead, expect more exchanges to copy Hong Kong’s R&D-friendly playbook. As AI, biotech, and clean energy startups burn cash before they earn it, eligibility tests built around innovation spend rather than historical profit will only become more relevant.
The growth enterprises market won’t replace main exchanges anytime soon. But it’s carving out a permanent, useful lane for the companies main boards simply aren’t built to handle yet.
FAQs
What does GEM stand for?
GEM stands for Growth Enterprise Market, a stock exchange board for fast-growing companies that don’t yet meet main board requirements. The Hong Kong version launched in 1999.
Who can list on the growth enterprises market?
Mostly small and medium-sized businesses, startups, and R&D-heavy firms with strong growth potential but limited profit history. Eligibility usually depends on revenue, market cap, or research spending instead of pure earnings.
Is investing in GEM-listed stocks risky?
Yes, more so than blue-chip stocks. Disclosure is heavy, but the “buyer beware” approach means investors carry more responsibility for due diligence, and prices can swing sharply.
How is GEM different from the Main Board?
The Main Board demands a longer profitability track record and larger market capitalization. GEM trades some of that scrutiny for easier access, aimed at companies still proving themselves.
Did the 2024 reforms actually help?
Early signs suggest yes. The new R&D eligibility test and streamlined transfer mechanism appear to be attracting innovation-focused companies that previously avoided GEM altogether.
The growth enterprises market isn’t flashy, and it never really has been. But for the right company at the right stage, it’s quietly become one of the more practical doors into public capital available today.
